Debut Biotech aspires to be the next big biotech company, and the two-year-old company believes cell-free enzymes are the way to go. To prove it, the company obtained $22.6 million in series A funding on Thursday. According to CEO Joshua Britton in an interview with Fierce Biotech, the new funds will be used to help build a 26,000-square-foot facility in San Diego that is expected to open in March or April of next year.
In the city, Debut has a 5,000-square-foot research and development centre. According to Britton, Debut is focused on expanding biomanufacturing faster and generating components that aren’t available from standard cell-based fermentation. Using sustainable feedstocks instead of petrochemicals, for example, is one example, according to the corporation.
Debut’s platform was also used by Royal DSM to develop natural components for use in personal health, food, and lifestyle goods. The deal, which was announced in May, begins with a proof of concept for Debut’s cell-free technique. Furthermore, the business will collaborate with nonprofit Battelle to transform energy-dense plastic garbage into new, useable materials for the DARPA ReSource initiative, reducing the military’s dependency on waste transportation and burning.